Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Miguel Martin

Showing results (181-190 of 278) with videos related to

Pageof 28
Sort By:
Molecular Cancer Therapeutics|February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid TumorsMatteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
BMC Cancer|June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
BMC Cancer|June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Cancer|July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNEEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Breast Cancer Research and Treatment|January 12, 2010
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo RegisterJavier Puente, Sara López-Tarruella, Amparo Ruiz, et al.
Breast Cancer Research and Treatment|March 27, 2010
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerCarlos H Barrios, Mei-Ching Liu, Soo Chin Lee, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.
JAMA Oncology|December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP GuidelinesMichael F Press, Jose A Seoane, Christina Curtis, et al.
Pageof 28

Showing results (181-190 of 278) with videos related to

Sort By:
Pageof 28
Molecular Cancer Therapeutics|February 8, 2022
A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid TumorsMatteo Duca, Darren Wan-Teck Lim, Vivek Subbiah, et al.
BMC Cancer|June 26, 2019
Correction to: Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
BMC Cancer|June 1, 2019
Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancerEdith A Perez, Sanne Lysbet de Haas, Wolfgang Eiermann, et al.
Breast (Edinburgh, Scotland)|April 26, 2017
The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?Matti Aapro, Michelino De Laurentiis, Dan Rea, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast CancerMatthew P Goetz, Erika P Hamilton, Mario Campone, et al.
Cancer|July 19, 2019
Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNEEdith A Perez, Carlos Barrios, Wolfgang Eiermann, et al.
Breast Cancer Research and Treatment|January 12, 2010
Practical prognostic index for patients with metastatic recurrent breast cancer: retrospective analysis of 2,322 patients from the GEICAM Spanish El Alamo RegisterJavier Puente, Sara López-Tarruella, Amparo Ruiz, et al.
Breast Cancer Research and Treatment|March 27, 2010
Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancerCarlos H Barrios, Mei-Ching Liu, Soo Chin Lee, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|August 27, 2016
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish RegionsJavier Salvador, Jorge Aparicio, Francisco Javier Baron, et al.
JAMA Oncology|December 7, 2018
Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP GuidelinesMichael F Press, Jose A Seoane, Christina Curtis, et al.
Pageof 28